Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral sodium phosphate (Z-521) in primary hypophosphatemic rickets
jRCT2080221295Phase 3
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sodium phosphate in familial hypophosphatemia, X-linked hypophosphataemia (XLH) and Hereditary Hypophosphatemic Rickets (XLH), sponsored by Zeria Pharmaceutical Co., Ltd.
02
Drugs
sodium phosphate
03
Conditions
familial hypophosphatemiaX-linked hypophosphataemia (XLH)Hereditary Hypophosphatemic Rickets (XLH)
Beyond the preview
Go deeper on jRCT2080221295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221295.